B
0.905
-0.03 (-3.13%)
| Previous Close | 0.934 |
| Open | 0.909 |
| Volume | 338,078 |
| Avg. Volume (3M) | 5,389,203 |
| Market Cap | 7,867,482 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 - 18 Nov 2024 |
| Diluted EPS (TTM) | -26.36 |
| Quarterly Earnings Growth (YOY) | 1,405.80% |
| Total Debt/Equity (MRQ) | 8.94% |
| Current Ratio (MRQ) | 3.85 |
| Return on Assets (TTM) | -62.13% |
| Return on Equity (TTM) | -116.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Silexion Therapeutics Corp | Bullish | - |
AIStockmoo Score
-0.6
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.63 |
|
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.98% |
| % Held by Institutions | 7.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wildcat Capital Management, Llc | 31 Dec 2024 | 113,428 |
| Meyer Handelman Co | 31 Mar 2025 | 32,967 |
| 52 Weeks Range | ||
| Median | 5.00 (452.43%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Maxim Group | 20 Mar 2025 | 5.00 (452.43%) | Buy | 1.11 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |